MedTrace Logo

Neurofeedback for Tinnitus - Does Frequency Specificity Matter?

NCT03550430 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2021-03-10

No results posted yet for this study

Summary

This study will evaluate the efficacy of an alpha/delta ratio (ADR) neurofeedback training protocol on tinnitus distress. 1/3 of the participants in the study will undergo ADR neurofeedback training, 1/3 an active comparator, beta/theta ratio (BTR) neurofeedback training, whilst the final 1/3 of participants will fill in daily diaries of tinnitus complaints and symptoms for two weeks.

Conditions

  • Tinnitus
  • Subjective Tinnitus
  • Chronic Tinnitus

Interventions

BEHAVIORAL

alpha/delta neurofeedback

neurofeedback training protocol seeking to decrease the alpha/delta ratio, by simultaneous rewarding alpha and inhibiting delta activity.

BEHAVIORAL

beta/theta neurofeedback

neurofeedback training protocol seeking to decrease the beta/theta ratio, by simultaneous rewarding beta and inhibiting theta activity.

OTHER

Diary completion

completion of diary relating to participants' experience of tinnitus intensity, interference, coping, harm and disability. Rated three times daily on numerical scale (0 - 10) for two weeks.

Sponsors & Collaborators

  • Eriksholm Research Centre

    collaborator OTHER

  • Linkoeping University

    collaborator OTHER_GOV

  • University Hospital of Gießen and Marburg

    collaborator UNKNOWN

  • Philipps University Marburg

    lead OTHER

Principal Investigators

  • Cornelia Weise, Dr. · Philipps Universität Marburg

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2020-08-31
Completion
2020-08-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03550430 on ClinicalTrials.gov